Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors

Kuniaki Shirao, Yasuhiro Matsumura, Yasuhide Yamada, Kei Muro, Masahiro Gotoh, Narikazu Boku, Atsushi Ohtsu, Fumio Nagashima, Yasushi Sano, Manabu Mutoh, Yusuke Tanigawara

研究成果: Article

19 引用 (Scopus)

抄録

Background: Oxaliplatin, a platinum compound, has been commonly used around the world for treating advanced colorectal cancer. The generally recommended dose and schedule of oxaliplatin monotherapy is 130 mg/m2 every 3 weeks. This trial was conducted to evaluate the safety and pharmacokinetics of oxaliplatin monotherapy in Japanese patients with solid tumors. Methods: Oxaliplatin was administered as a 2-h intravenous infusion every 3 weeks at a dose of 90 and 130 mg/m2. Blood was collected to determine the total platinum and the ultrafiltrate platinum concentrations in plasma in all cycles. Results: Nine patients were enrolled; three were given oxaliplatin monotherapy at 90 mg/m2 and six received 130 mg/m2. All tumors were colorectal cancer. The major adverse reactions included myelosuppressive, neurological and gastrointestinal toxicities, although most were grades 1 and 2 at both dose levels. Peripheral sensory neuropathy of without movement disturbance (grade 1 or 2) was observed in all patients at both dose levels. The 130 mg/m2 dose level was not found to be the maximum tolerated dose, but was judged to be the recommended dose. No objective responses were seen and five cases of no change were observed. A bi-exponential open model best described the disappearance of platinum in the plasma, and a tri-exponential open model best described the disappearance of ultrafilterable platinum in the plasma at both dose levels. No racial difference was suggested in the pharmacokinetics of oxaliplatin. Conclusions: The oxaliplatin monotherapy dose schedule of 130 mg/m2 every 3 weeks, recommended worldwide, is acceptable for Japanese patients.

元の言語English
ページ(範囲)295-300
ページ数6
ジャーナルJapanese Journal of Clinical Oncology
36
発行部数5
DOI
出版物ステータスPublished - 2006 5

Fingerprint

oxaliplatin
Platinum
Neoplasms
Colorectal Neoplasms
Appointments and Schedules
Pharmacokinetics
Platinum Compounds
Maximum Tolerated Dose
Peripheral Nervous System Diseases
Intravenous Infusions

ASJC Scopus subject areas

  • Oncology

これを引用

Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. / Shirao, Kuniaki; Matsumura, Yasuhiro; Yamada, Yasuhide; Muro, Kei; Gotoh, Masahiro; Boku, Narikazu; Ohtsu, Atsushi; Nagashima, Fumio; Sano, Yasushi; Mutoh, Manabu; Tanigawara, Yusuke.

:: Japanese Journal of Clinical Oncology, 巻 36, 番号 5, 05.2006, p. 295-300.

研究成果: Article

Shirao, K, Matsumura, Y, Yamada, Y, Muro, K, Gotoh, M, Boku, N, Ohtsu, A, Nagashima, F, Sano, Y, Mutoh, M & Tanigawara, Y 2006, 'Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors', Japanese Journal of Clinical Oncology, 巻. 36, 番号 5, pp. 295-300. https://doi.org/10.1093/jjco/hyl016
Shirao, Kuniaki ; Matsumura, Yasuhiro ; Yamada, Yasuhide ; Muro, Kei ; Gotoh, Masahiro ; Boku, Narikazu ; Ohtsu, Atsushi ; Nagashima, Fumio ; Sano, Yasushi ; Mutoh, Manabu ; Tanigawara, Yusuke. / Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. :: Japanese Journal of Clinical Oncology. 2006 ; 巻 36, 番号 5. pp. 295-300.
@article{c8cfc21becf440d1928ce21cac9930b1,
title = "Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors",
abstract = "Background: Oxaliplatin, a platinum compound, has been commonly used around the world for treating advanced colorectal cancer. The generally recommended dose and schedule of oxaliplatin monotherapy is 130 mg/m2 every 3 weeks. This trial was conducted to evaluate the safety and pharmacokinetics of oxaliplatin monotherapy in Japanese patients with solid tumors. Methods: Oxaliplatin was administered as a 2-h intravenous infusion every 3 weeks at a dose of 90 and 130 mg/m2. Blood was collected to determine the total platinum and the ultrafiltrate platinum concentrations in plasma in all cycles. Results: Nine patients were enrolled; three were given oxaliplatin monotherapy at 90 mg/m2 and six received 130 mg/m2. All tumors were colorectal cancer. The major adverse reactions included myelosuppressive, neurological and gastrointestinal toxicities, although most were grades 1 and 2 at both dose levels. Peripheral sensory neuropathy of without movement disturbance (grade 1 or 2) was observed in all patients at both dose levels. The 130 mg/m2 dose level was not found to be the maximum tolerated dose, but was judged to be the recommended dose. No objective responses were seen and five cases of no change were observed. A bi-exponential open model best described the disappearance of platinum in the plasma, and a tri-exponential open model best described the disappearance of ultrafilterable platinum in the plasma at both dose levels. No racial difference was suggested in the pharmacokinetics of oxaliplatin. Conclusions: The oxaliplatin monotherapy dose schedule of 130 mg/m2 every 3 weeks, recommended worldwide, is acceptable for Japanese patients.",
keywords = "Oxaliplatin, Pharmacokinetics, Phase I study, Safety",
author = "Kuniaki Shirao and Yasuhiro Matsumura and Yasuhide Yamada and Kei Muro and Masahiro Gotoh and Narikazu Boku and Atsushi Ohtsu and Fumio Nagashima and Yasushi Sano and Manabu Mutoh and Yusuke Tanigawara",
year = "2006",
month = "5",
doi = "10.1093/jjco/hyl016",
language = "English",
volume = "36",
pages = "295--300",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors

AU - Shirao, Kuniaki

AU - Matsumura, Yasuhiro

AU - Yamada, Yasuhide

AU - Muro, Kei

AU - Gotoh, Masahiro

AU - Boku, Narikazu

AU - Ohtsu, Atsushi

AU - Nagashima, Fumio

AU - Sano, Yasushi

AU - Mutoh, Manabu

AU - Tanigawara, Yusuke

PY - 2006/5

Y1 - 2006/5

N2 - Background: Oxaliplatin, a platinum compound, has been commonly used around the world for treating advanced colorectal cancer. The generally recommended dose and schedule of oxaliplatin monotherapy is 130 mg/m2 every 3 weeks. This trial was conducted to evaluate the safety and pharmacokinetics of oxaliplatin monotherapy in Japanese patients with solid tumors. Methods: Oxaliplatin was administered as a 2-h intravenous infusion every 3 weeks at a dose of 90 and 130 mg/m2. Blood was collected to determine the total platinum and the ultrafiltrate platinum concentrations in plasma in all cycles. Results: Nine patients were enrolled; three were given oxaliplatin monotherapy at 90 mg/m2 and six received 130 mg/m2. All tumors were colorectal cancer. The major adverse reactions included myelosuppressive, neurological and gastrointestinal toxicities, although most were grades 1 and 2 at both dose levels. Peripheral sensory neuropathy of without movement disturbance (grade 1 or 2) was observed in all patients at both dose levels. The 130 mg/m2 dose level was not found to be the maximum tolerated dose, but was judged to be the recommended dose. No objective responses were seen and five cases of no change were observed. A bi-exponential open model best described the disappearance of platinum in the plasma, and a tri-exponential open model best described the disappearance of ultrafilterable platinum in the plasma at both dose levels. No racial difference was suggested in the pharmacokinetics of oxaliplatin. Conclusions: The oxaliplatin monotherapy dose schedule of 130 mg/m2 every 3 weeks, recommended worldwide, is acceptable for Japanese patients.

AB - Background: Oxaliplatin, a platinum compound, has been commonly used around the world for treating advanced colorectal cancer. The generally recommended dose and schedule of oxaliplatin monotherapy is 130 mg/m2 every 3 weeks. This trial was conducted to evaluate the safety and pharmacokinetics of oxaliplatin monotherapy in Japanese patients with solid tumors. Methods: Oxaliplatin was administered as a 2-h intravenous infusion every 3 weeks at a dose of 90 and 130 mg/m2. Blood was collected to determine the total platinum and the ultrafiltrate platinum concentrations in plasma in all cycles. Results: Nine patients were enrolled; three were given oxaliplatin monotherapy at 90 mg/m2 and six received 130 mg/m2. All tumors were colorectal cancer. The major adverse reactions included myelosuppressive, neurological and gastrointestinal toxicities, although most were grades 1 and 2 at both dose levels. Peripheral sensory neuropathy of without movement disturbance (grade 1 or 2) was observed in all patients at both dose levels. The 130 mg/m2 dose level was not found to be the maximum tolerated dose, but was judged to be the recommended dose. No objective responses were seen and five cases of no change were observed. A bi-exponential open model best described the disappearance of platinum in the plasma, and a tri-exponential open model best described the disappearance of ultrafilterable platinum in the plasma at both dose levels. No racial difference was suggested in the pharmacokinetics of oxaliplatin. Conclusions: The oxaliplatin monotherapy dose schedule of 130 mg/m2 every 3 weeks, recommended worldwide, is acceptable for Japanese patients.

KW - Oxaliplatin

KW - Pharmacokinetics

KW - Phase I study

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=33745700671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745700671&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyl016

DO - 10.1093/jjco/hyl016

M3 - Article

C2 - 16702162

AN - SCOPUS:33745700671

VL - 36

SP - 295

EP - 300

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

ER -